Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity?

Expert Opin Biol Ther. 2020 Aug;20(8):831-836. doi: 10.1080/14712598.2020.1767062. Epub 2020 May 26.

Authors

Leticia Moreno-Fierros¹, Ileana García-Silva², Sergio Rosales-Mendoza²

Affiliations

¹ Faculty of Higher Studies Iztacala, National Autonomous University of Mexico , Tlalnepantla, Estado De México, México.
² Faculty of Chemical Sciences and Center for Health Sciences, Autonomous University of San Luis Potosí , San Luis Potosi, México.

PMID: 32380868
DOI: 10.1080/14712598.2020.1767062

No abstract available

Keywords: COVID-19; Oral vaccine; intranasal vaccine; mucosal adjuvant; sIgA.

Publication types

Editorial